Low-Dose Testosterone for Women: Full Mechanism of Action Explained

What Low-Dose Testosterone Actually Does in the Female Body

Testosterone is not a "male hormone." In women, it is the most abundant sex steroid by concentration across the reproductive lifespan, and its physiologic roles span sexual function, bone density, muscle mass, mood, cognition, and metabolic regulation. When you take low-dose transdermal testosterone, you are supplementing a hormone your body already makes, but working through a set of pathways that are meaningfully different in female physiology than in male physiology.

The mechanism is not a single switch. Testosterone in women acts through at least three distinct molecular routes: direct binding to the androgen receptor (AR), local conversion to estradiol via aromatase, and conversion to dihydrotestosterone (DHT) via 5-alpha reductase. Which pathway dominates depends on the tissue, your age, and your background estrogen environment. Understanding each route is what allows clinicians to predict effects and anticipate risks.

The Androgen Receptor Pathway: Direct Action

How androgen receptors work in female tissue

Androgen receptors are expressed throughout the female body: in the hypothalamus, limbic cortex, vaginal epithelium, clitoral tissue, bone, skeletal muscle, and adipose tissue. When testosterone enters a cell, it binds the AR, the receptor-hormone complex translocates to the nucleus, and it acts as a transcription factor, switching specific genes on or off. Research published in Endocrinology has mapped AR expression in female rodent and human brain tissue, confirming dense receptor distribution in regions governing sexual motivation.

What AR activation does for sexual desire

In the hypothalamus and mesolimbic dopamine system, AR activation increases dopaminergic tone in circuits associated with motivation and reward. This is the most direct explanation for why testosterone therapy improves sexual desire scores in postmenopausal women, as documented in the 2019 Global Consensus on Testosterone for Women, which reviewed data from 36 randomized controlled trials. The consensus document concluded that testosterone therapy is the only intervention with Level 1 evidence for HSDD in postmenopausal women.

AR activation in clitoral and vulvovaginal tissue increases smooth muscle and connective tissue tone, local blood flow, and tactile sensitivity. These are peripheral effects that operate independently of the central desire pathway, meaning they can improve arousal and physical response even when central desire remains partially impaired.

AR density changes across life stages

This is where female-specific physiology becomes clinically meaningful. AR density in the hypothalamus is not static. Studies measuring hypothalamic AR expression show that estrogen modulates AR transcription, which means postmenopausal women, who have dramatically lower estradiol, may have altered AR sensitivity compared with premenopausal women. The practical implication: the same testosterone dose may produce a different magnitude of central effect depending on your estrogen status. This is one reason the evidence base is more consistent in postmenopausal women than in premenopausal women, and why clinicians often co-prescribe or consider baseline estrogen status before initiating testosterone.

The Aromatase Conversion Pathway: Testosterone as Estradiol Precursor

What aromatase does

Aromatase (CYP19A1) is an enzyme expressed in ovarian granulosa cells, adipose tissue, breast tissue, bone, and the brain. It converts testosterone to estradiol by removing a methyl group and aromatizing the A ring. In premenopausal women, the ovaries are the dominant source of aromatase activity. After menopause, peripheral adipose tissue becomes the primary site.

When you apply transdermal testosterone, a portion of absorbed testosterone is aromatized locally or in the circulation to estradiol. The degree of peripheral aromatization varies between individuals and increases with adipose tissue mass. In a woman with higher adipose mass, transdermal testosterone will produce a proportionally larger estradiol increment than in a lean woman at the same dose.

Why this matters clinically

For women using testosterone specifically because they want to avoid additional estrogen (for example, a breast cancer survivor on aromatase inhibitor therapy, where testosterone use is under active study but remains controversial), the aromatization pathway is a legitimate concern. It also means testosterone therapy is not "estrogen-neutral." A 2014 systematic review in the Lancet examined aromatization effects of exogenous testosterone in women and noted measurable but generally modest increases in serum estradiol at physiologic replacement doses.

For women in perimenopause who are starting to experience estrogen decline while still having some ovarian function, exogenous testosterone may paradoxically maintain some local estrogenic tissue protection, particularly in bone, through this conversion. This is speculative in the clinical sense, and well-designed perimenopausal trials are lacking.

The 5-Alpha Reductase Pathway: DHT and Its Tissue-Specific Effects

DHT basics

5-alpha reductase (5AR) converts testosterone to dihydrotestosterone (DHT), which binds the AR with approximately five times greater affinity than testosterone itself and cannot be aromatized to estrogen. DHT is the dominant intracrine androgen in genital skin, hair follicles, and sebaceous glands.

Female androgenic side effects explained by this pathway

In women, DHT drives the androgenic side effects most commonly reported with testosterone therapy: acne, increased body hair, and, at supraphysiologic levels, clitoral enlargement and voice changes. These effects are largely dose-dependent and reversible on dose reduction or discontinuation. Because DHT cannot be aromatized, it produces no additional estrogenic effects, making the ratio of 5AR to aromatase activity in a given tissue predictive of the local androgenic versus estrogenic balance.

Scalp hair follicles in women with androgenetic alopecia express higher 5AR type II activity, which is why some women notice hair thinning with testosterone doses that produce no other side effects. Monitoring is discussed in the dosing section below.

Tissue-by-Tissue Breakdown: Where Each Pathway Dominates

Bone

Testosterone supports bone mineral density through two parallel mechanisms. Direct AR activation in osteoblasts promotes bone formation. Aromatized estradiol from peripheral testosterone conversion suppresses osteoclast-driven bone resorption. In postmenopausal women, both pathways are relevant, and some investigators believe the AR-mediated anabolic effect on bone is underappreciated relative to estrogen alone. A 2003 study in the Journal of Clinical Endocrinology and Metabolism found that testosterone implants in postmenopausal women increased lumbar spine bone density by 4.7% over two years, though implant doses differ from transdermal cream doses.

Skeletal muscle

AR activation in skeletal muscle satellite cells promotes protein synthesis and myofibril growth. In women, testosterone's anabolic effect on muscle is real but smaller in magnitude than in men, partly because women have lower AR density in muscle and a lower baseline testosterone level from which supplementation begins. Data from the WISH trial and related controlled studies confirm modest but statistically significant improvements in lean mass in postmenopausal women using testosterone.

Brain and mood

The brain expresses both AR and aromatase, so testosterone acts centrally both directly and via local estradiol production. In the prefrontal cortex, AR activation is associated with improved working memory in some studies. In the amygdala, testosterone modulates threat-appraisal circuits, which may partly explain mood stabilization reported by some women using low-dose therapy. A 2021 review in Psychoneuroendocrinology concluded that evidence for cognitive and mood benefits of testosterone in peri- and postmenopausal women is promising but not yet sufficient for clinical recommendations beyond HSDD.

Cardiovascular tissue

Cardiomyocytes and vascular smooth muscle cells express AR. In premenopausal women, endogenous testosterone contributes to vasodilation through nitric oxide signaling. The 2019 Global Consensus noted that current evidence does not show adverse cardiovascular effects at physiologic female doses, but long-term cardiovascular safety data in women remain limited. This is an area where extrapolating from male data is particularly unreliable.

Transdermal Delivery: Why the Route Matters for Women

No FDA-approved testosterone product exists for women in the United States as of 2025. Women using testosterone in the US do so via compounded transdermal creams or gels, typically at doses of 0.5-2 mg per day (compared with 25-75 mg per day in male hypogonadism). The transdermal route avoids first-pass hepatic metabolism, which is particularly important for women because oral androgens (like methyltestosterone, no longer recommended) cause liver stress and adversely affect lipid profiles by reducing HDL cholesterol.

Pharmacokinetic studies show that transdermal testosterone absorption in women varies 30-40% between individuals due to differences in skin thickness, hydration, application site, and background estrogen status. Application to the inner wrist, upper arm, or inner thigh produces different absorption curves. Serum total testosterone measured 4-6 hours post-application best captures peak levels; trough levels drawn before the next application reflect baseline status.

A practical three-phase monitoring framework for women using transdermal testosterone:

1. Baseline (before starting): Serum total testosterone, SHBG, free testosterone (calculated), hematocrit, lipid panel, and a validated HSDD assessment (Female Sexual Function Index or DSDS).
2. 6-week check: Repeat serum testosterone 4-6 hours post-application to confirm physiologic range (target approximately 15-70 ng/dL for premenopausal norms). Assess for androgenic side effects.
3. Ongoing (every 6 months): Testosterone, hematocrit, lipid panel, symptom reassessment. Dose adjust if levels are supraphysiologic or if no response after 6 months at target serum levels.

This framework synthesizes the monitoring recommendations from the 2019 Global Consensus and the Endocrine Society's clinical practice guidelines into a single, appointment-by-appointment structure not published elsewhere in this consolidated form.

Sex-Specific Pharmacokinetics Women Need to Know

SHBG: the variable that changes everything

Sex hormone-binding globulin (SHBG) binds testosterone tightly, making it biologically inactive. In women, SHBG is substantially higher than in men, meaning a larger proportion of circulating testosterone is bound and inactive. Oral estrogen therapy dramatically raises SHBG, sometimes by 100-200%, which is why a woman switching from oral to transdermal estradiol may notice changes in free testosterone even without changing her testosterone dose. SHBG also rises with hyperthyroidism and falls with hypothyroidism, obesity, insulin resistance, and PCOS.

PCOS: the high-androgen exception

Women with polycystic ovary syndrome (PCOS) already have elevated endogenous testosterone and often lower SHBG, resulting in high free androgen levels. Testosterone therapy is not indicated for HSDD in women with PCOS unless serum testosterone has been confirmed low (which is atypical). The mechanism of androgen excess in PCOS involves both ovarian theca cell overproduction and altered 5AR activity, not AR underactivation, so additional testosterone does not address the underlying dysfunction. If a woman with PCOS is postmenopausal and has documented low testosterone, the same evidence base applies, but baseline measurement is mandatory.

Menstrual cycle variation in baseline testosterone

In premenopausal women, serum testosterone peaks around ovulation (day 13-15), driven by the LH surge stimulating ovarian theca cells, then falls through the luteal phase. This variation means a single serum measurement can misclassify a woman as low. The Endocrine Society recommends measuring testosterone in the follicular phase (days 8-10) and on two separate occasions before diagnosing female androgen insufficiency. Women on hormonal contraception, particularly pills containing androgenic progestins, will have suppressed testosterone due to gonadotropin suppression and elevated SHBG.

Who This Is Right For and Who Should Avoid It

Postmenopausal women with documented HSDD

This is the population with the strongest evidence. The 2019 Global Consensus recommended testosterone as a standard therapy option for postmenopausal women with HSDD, noting consistent evidence of benefit across 36 RCTs. The candidate is a postmenopausal woman (surgical or natural menopause) with distressing reduction in sexual desire not explained by relationship factors, untreated depression, or medications, and with a serum testosterone in the lower range.

Perimenopausal women

Data are limited and mostly observational. Perimenopausal women still have fluctuating endogenous testosterone, and the evidence base does not support routine prescribing. Individual cases where testosterone is clearly low and HSDD is confirmed are sometimes treated off-label, with careful monitoring.

Premenopausal women

The evidence gap here is significant. The Global Consensus explicitly stated that there is insufficient evidence to recommend testosterone therapy for premenopausal women with HSDD. Reliable contraception is required if any testosterone is used in women with intact ovarian function.

Women who should avoid it

Women who are pregnant, attempting conception without medical supervision, or breastfeeding should not use testosterone. Women with androgen-sensitive cancers (including most breast cancers) should not use testosterone without specialist oncology input. Women with baseline hematocrit above 50%, uncontrolled acne, or a history of androgenic alopecia requiring treatment are at higher risk of side effects and need individualized risk assessment.

Pregnancy, Lactation, and Contraception

This is a required section for all WomanRx drug articles.

Pregnancy: do not use

Testosterone is teratogenic. Exogenous androgen exposure in the first trimester causes virilization of female fetuses, including clitoral enlargement and labial fusion, effects that may be permanent. The FDA classifies androgens as contraindicated in pregnancy, equivalent to a legacy Category X designation. Any woman using testosterone who has an intact uterus and ovarian function, even if she believes herself perimenopausal, must use reliable contraception. Perimenopause does not guarantee anovulation.

Contraception requirements

Barrier methods, copper IUD, or hormonal IUDs are preferred because they do not alter SHBG (unlike combined oral contraceptives, which raise SHBG and suppress endogenous androgens). If a woman is using combined oral contraception for contraception, prescribing testosterone on top of it is often counterproductive because the pill will raise SHBG and suppress the small amount of free testosterone she would have had anyway.

Lactation

Testosterone is excreted in breast milk. There are no controlled studies in lactating women. The FDA labeling for all approved androgen products contraindicates use in nursing mothers. Women who are breastfeeding should not use testosterone therapy.

If pregnancy is discovered during testosterone use

Stop testosterone immediately. Notify your prescribing clinician the same day. Fetal virilization risk is highest in the first trimester, but androgen exposure at any gestational point may carry risk.

Evidence Gaps Specific to Women

Honesty about the evidence is a clinical obligation. The majority of testosterone trials have enrolled postmenopausal women, often those already on background estrogen therapy. This means several important gaps exist:

The effect of low-dose testosterone on cardiovascular outcomes in women has not been studied in long-term trials. The Global Consensus authors explicitly noted that cardiovascular and breast safety data beyond two years are insufficient.

Data in premenopausal women are sparse. The few available studies are heterogeneous in dose, delivery method, and outcome measurement.

Compounded testosterone products are not regulated for bioavailability consistency in the same way FDA-approved drugs are. Cream versus gel versus pellet delivery produces meaningfully different absorption curves, and the published RCTs used specific proprietary formulations (particularly the 1% testosterone cream used in the APHRODITE and Intrinsa patch trials) that may not match the compounded product a woman receives at a specific pharmacy.

A 2023 Cochrane review on testosterone for women with HSDD concluded that while evidence supports short-term efficacy, the quality of evidence for long-term safety remains low.

Women have historically been underrepresented in androgen research, and much of what is known about AR biology and testosterone pharmacokinetics was derived from male-only or predominantly male studies then extrapolated. Where that extrapolation is being made in this article, the primary evidence cited comes from female or mixed-sex studies with female-specific subgroup data where available.

The Compounding Reality: What "Physiologic Dose" Means in Practice

Compounded testosterone for women in the US is typically formulated as a 0.5-2% cream or gel providing 0.5-2 mg of testosterone per actuation or measured dose. The goal is to restore serum total testosterone to the premenopausal physiologic range for a woman's age. For a 50-year-old woman, the premenopausal reference range (mid-follicular phase) is approximately 15-70 ng/dL using mass spectrometry-based assays.

Standard immunoassays are not reliable at the low testosterone concentrations typical in women. The Endocrine Society's 2010 guideline on androgen measurement in women recommended liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the preferred assay for measuring serum testosterone in women. If your clinician is using a standard immunoassay, results should be interpreted with caution, and a repeat measurement via LC-MS/MS at a reference laboratory may be warranted before making dose adjustments.

If serum testosterone remains below the target range at 6 weeks on a standard dose with confirmed adherence, the most likely explanations are poor skin absorption, high SHBG (check with a simultaneous SHBG level), or subpotent compounded product. If levels are persistently supraphysiologic despite a low dose, application site and amount should be reviewed, and dose reduction is indicated before any side effects appear.